Gene: NLGN1

22871
NL1
neuroligin 1
protein-coding
3q26.31
Ensembl:ENSG00000169760 MIM:600568 Vega:OTTHUMG00000157005 UniprotKB:Q8N2Q7
NG_046919.1
PubMed
0   ANCO-SNPs
CD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.927e-1 (AD)  7.026e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTMR70.876
MBLAC20.87
UBR30.869
ZNF7110.868
BDP10.867
LRRTM30.867
CHM0.865
CSNK1G30.865
ATE10.864
SLC25A460.862

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.453
SIX5-0.437
SYDE1-0.426
RHOD-0.419
A4GALT-0.407
EVC2-0.404
SOD3-0.399
FOXJ1-0.397
OR4F5-0.397
CCDC102A-0.396

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of NLGN1 mRNA"28973690
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of NLGN1 mRNA25607892
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of NLGN1 gene27153756
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
D001151ArsenicArsenic affects the methylation of NLGN1 gene25304211
C006632arsenic trioxidearsenic trioxide results in decreased expression of NLGN1 mRNA26705709
C006632arsenic trioxidearsenic trioxide results in increased expression of NLGN1 mRNA20458559
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of NLGN1 mRNA26001963
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of NLGN1 mRNA20106945
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased mutagenesis of NLGN1 gene25435355
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of NLGN1 mRNA25181051
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA25607892
D002392Catechin[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of NLGN1 mRNA24763279
D003471CuprizoneCuprizone results in decreased expression of NLGN1 mRNA26577399
D016572CyclosporineCyclosporine results in decreased expression of NLGN1 mRNA20106945
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
C118739entinostatentinostat results in decreased expression of NLGN1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
D005419FlavonoidsFlavonoids results in decreased expression of NLGN1 mRNA18035473
C511402Grape Seed Proanthocyanidins[Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of NLGN1 mRNA24763279
C010176halofuginonehalofuginone results in increased expression of NLGN1 mRNA17180598
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of NLGN1 mRNA24796395
D007854LeadLead affects the expression of NLGN1 mRNA28903495
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of NLGN1 mRNA"20188158
C044387N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine"N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased expression of NLGN1 mRNA"12756304
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of NLGN1 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of NLGN1 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of NLGN1 mRNA25607892
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 gene polymorphism affects the susceptibility to [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of NLGN1 mRNA]"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased expression of NLGN1 mRNA"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 protein affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased expression of NLGN1 mRNA]"21673326
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of NLGN1 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of NLGN1 mRNA19710929
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of NLGN1 mRNA19710929
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892
D014212TretinoinTretinoin results in increased expression of NLGN1 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of NLGN1 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of NLGN1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of NLGN1 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of NLGN1 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of NLGN1 gene25560391
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA25607892

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0001540amyloid-beta binding-NAS21838267  
GO:0030165PDZ domain binding-IDA17474715  
GO:0038023signaling receptor activity-ISS-  
GO:0042043neurexin family protein binding-IBA21873635  
GO:0042043neurexin family protein binding-ISS-  
GO:0042043neurexin family protein binding-NAS14522992  
GO:0046983protein dimerization activity-ISS-  
GO:0050839cell adhesion molecule binding-ISS-  
GO:0097110scaffold protein binding-IDA17474715  
GO ID GO Term Qualifier Evidence PubMed
GO:0002087regulation of respiratory gaseous exchange by neurological system process-IEA-  
GO:0006605protein targeting-ISS-  
GO:0007157heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules-ISS-  
GO:0007158neuron cell-cell adhesion-IBA21873635  
GO:0007158neuron cell-cell adhesion-ISS-  
GO:0007158neuron cell-cell adhesion-NAS25428619  
GO:0007158neuron cell-cell adhesion-TAS15797875  
GO:0007399nervous system development-ISS-  
GO:0007416synapse assembly-ISS-  
GO:0010841positive regulation of circadian sleep/wake cycle, wakefulness-ISS-  
GO:0016080synaptic vesicle targeting-ISS-  
GO:0016339calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules-ISS-  
GO:0023041neuronal signal transduction-TAS15797875  
GO:0031175neuron projection development-IDA22750515  
GO:0031175neuron projection development-ISS-  
GO:0032230positive regulation of synaptic transmission, GABAergic-ISS-  
GO:0035418protein localization to synapse-ISS-  
GO:0045184establishment of protein localization-ISS-  
GO:0045664regulation of neuron differentiation-ISS-  
GO:0048511rhythmic process-IEA-  
GO:0048789cytoskeletal matrix organization at active zone-ISS-  
GO:0050804modulation of chemical synaptic transmission-IBA21873635  
GO:0050804modulation of chemical synaptic transmission-ISS-  
GO:0051260protein homooligomerization-ISS-  
GO:0051290protein heterotetramerization-IEA-  
GO:0051491positive regulation of filopodium assembly-ISS-  
GO:0051965positive regulation of synapse assembly-IDA24613359  
GO:0051965positive regulation of synapse assembly-ISS-  
GO:0051968positive regulation of synaptic transmission, glutamatergic-ISS-  
GO:0060291long-term synaptic potentiation-IEA-  
GO:0060999positive regulation of dendritic spine development-IGI23143522  
GO:0060999positive regulation of dendritic spine development-ISS-  
GO:0061002negative regulation of dendritic spine morphogenesis-IGI23143522  
GO:0071277cellular response to calcium ion-ISS-  
GO:0072553terminal button organization-ISS-  
GO:0097091synaptic vesicle clustering-ISS-  
GO:0097104postsynaptic membrane assembly-IBA21873635  
GO:0097104postsynaptic membrane assembly-ISS-  
GO:0097105presynaptic membrane assembly-IBA21873635  
GO:0097105presynaptic membrane assembly-ISS-  
GO:0097113AMPA glutamate receptor clustering-ISS-  
GO:0097114NMDA glutamate receptor clustering-ISS-  
GO:0097115neurexin clustering involved in presynaptic membrane assembly-ISS-  
GO:0097119postsynaptic density protein 95 clustering-ISS-  
GO:0097120receptor localization to synapse-ISS-  
GO:0098942retrograde trans-synaptic signaling by trans-synaptic protein complex-IEA-  
GO:0099054presynapse assembly-TAS21838267  
GO:0099560synaptic membrane adhesion-IEA-  
GO:0140058neuron projection arborization-ISS-  
GO:1900029positive regulation of ruffle assembly-ISS-  
GO:1900244positive regulation of synaptic vesicle endocytosis-ISS-  
GO:1902474positive regulation of protein localization to synapse-IEA-  
GO:1902533positive regulation of intracellular signal transduction-ISS-  
GO:1904861excitatory synapse assembly-ISS26440732  
GO:1905520positive regulation of presynaptic active zone assembly-IEA-  
GO:2000302positive regulation of synaptic vesicle exocytosis-ISS-  
GO:2000310regulation of NMDA receptor activity-IGI23143522  
GO:2000310regulation of NMDA receptor activity-ISS-  
GO:2000311regulation of AMPA receptor activity-ISS-  
GO:2000463positive regulation of excitatory postsynaptic potential-IGI23143522  
GO:2000463positive regulation of excitatory postsynaptic potential-ISS-  
GO:2000809positive regulation of synaptic vesicle clustering-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005794Golgi apparatus-ISS-  
GO:0005886plasma membrane-ISS-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-ISS-  
GO:0005887integral component of plasma membrane-NAS14522992  
GO:0009897external side of plasma membrane-IEA-  
GO:0009986cell surface-IBA21873635  
GO:0009986cell surface-ISS26440732  
GO:0014069postsynaptic densitycolocalizes_withISS-  
GO:0014069postsynaptic density-TAS15797875  
GO:0017146NMDA selective glutamate receptor complex-IEA-  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-ISS-  
GO:0032433filopodium tip-ISS-  
GO:0043197dendritic spine-ISS-  
GO:0043198dendritic shaft-IEA-  
GO:0045202synapse-IBA21873635  
GO:0045202synapse-ISS-  
GO:0060076excitatory synapse-NAS25428619  
GO:0089717spanning component of membrane-TAS21838267  
GO:0098793presynapse-IEA-  
GO:0098794postsynapse-NAS14522992  
GO:0098985asymmetric, glutamatergic, excitatory synapse-TAS21838267  
GO:0099055integral component of postsynaptic membrane-TAS15797875  
KEGG ID KEGG Term
hsa04514Cell adhesion molecules (CAMs)
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemIEA
R-HSA-112316Neuronal SystemTAS
R-HSA-6794361Neurexins and neuroliginsIEA
R-HSA-6794361Neurexins and neuroliginsTAS
R-HSA-6794362Protein-protein interactions at synapsesIEA
R-HSA-6794362Protein-protein interactions at synapsesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
18418251Nrxn3 upregulation in the globus pallidus of mice developing cocaine addiction. (2008 May 7)Kelai SNeuroreport